

## **Company Report**

## New China Life (1336 HK) – Hold Life & Health Insurance Industry

2013E target price: HK\$34.30 (from HK\$24.85 previously)

## Rallying only on A-share market rebound

Recently, New China Life outperformed its peers and benchmark indices, only due to its big EV increment led by A-share market rebound. The company is the only insurer reporting a decelerating premium growth towards end-2012. Also, it reported the lowest NBM among peers in 1H12. Other than being cheap, we see minimal merits for the insurer. Based on these, we maintain HOLD on New China Life. But we upgrade its TP to HK\$34.30 (HK\$24.85 previously) due to better investment assumptions.

Only life insurer with a decelerating premium growth. Its premium growth decelerated to 3.9% YoY in 11M12, compared to the year high of a 20.0% YoY. Such trend is the worst among peers. New China Life lacks new products with competitiveness. Per our estimates, New China Life will report a NBM of 23.0% and VNB growth of 4.6% YoY in this year.

With the lowest NBM with no proper reason. New China Life reported its NBM at 23.3% in 1H12. It has improved by only 0.9ppt HoH. Also, its NBM is the lowest among peers. It is inconceivable as the insurer has shifted sales focus to 10-years plus duration products during 2012. NBM should have advanced further on lengthening product duration.

**Rising only on A-share market rally.** Per our analysis, New China Life's EV rose by 10.6% due to the recent 17.7% rally of A-share markets. In our opinion, this is the only reason for its recent outperformance.

**Trading at a low valuation still.** New China Life is trading at 1.07x 2013E PEV, cheaper than 1.25x of sector average. Therefore, we remain Neutral on its share price outlook, despite its weak fundamentals.

**Maintain HOLD; upgrade TP to HK\$34.30.** We derive an appraisal value of Rmb84,510 mn for 2013E, also adopting it as TP, or HK\$34.30 / share (HK\$24.85 previously). The implied valuation of our TP is 1.17x 2013E PEV and 2.7x 2013E VNB. This represents 9.1% upside potential from the current share price. We maintain HOLD on New China Life.

**Risk factors:** better or worse-than-expected underwriting and investment performance, looser or tighter-than-expected regulations

## Results and valuation

FY ended Dec 31	2010	2011	2012E	2013E	2014E
Revenue (Rmb mn)	102,709	108,610	121,366	140,699	158,647
Chg (YoY)	39.0	5.7	11.7	15.9	12.8
Net profit (Rmb mn)	2,249	2,799	3,615	4,578	5,064
Chg (YoY)	(15.5)	24.5	29.1	26.6	10.6
EPS (HK\$)	2.23	1.51	1.44	1.86	2.09
PER (x)	11.1	16.4	21.8	16.9	15.1
BPS (HK\$)	6.5	12.3	14.9	17.3	19.8
P/B(x)	3.8	2.0	2.1	1.8	1.6
EVPS (HK\$)	27.9	19.1	24.2	29.4	35.3
PEV (x)	0.9	1.3	1.3	1.1	0.9
VNB (HK\$)	4.71	1.70	1.74	1.82	1.94
VNB (x)	(0.6)	3.4	4.2	1.1	(2.0)

Source: Company data, ABCI Securities estimates

#### Key data H-share price (HK\$) 31.45 34.30 Target price (HK\$) Upside potential (%) 9.1 36.9 / 22.3 52Wk H/L(HK\$) Issued shares: 1.034 H-shares (mn) A-shares (mn) 2,083 H-share mkt cap (HK\$mn) 102,528 30-day avg vol (HK\$mn) 101.4 Major shareholder (%): Central Huijin 31.2

Source: Company & Bloomberg

#### Revenue breakdown in 2011 (%)

Net earned premiums (NEP)	88.1
Investment income	11.7
Other income	0.2

15.1

\*Based on 2011 results Source: Company

Baosteel Group

Share performance (%)

	Absolute	Relative*
1-mth	15.2	11.4
3-mth	23.3	12.1
6-mth	9.3	(10.3)

\*Relative to MSCI China Source: Bloomberg

#### 1 year price performance



Source: Bloomberg

Analyst

Report Date: 14 January 2013

Name: Francis Chan Tel: (852) 2147 8311

Email: francischan@abci.com.hk



## New China Life: 1H12 profit & loss

	2009	2010	2011	1H10	2H10	1H11	2H11	1H12	HoH	YoY
	RMBmn	RMBmn	RMBmn	RMBmn	RMBmn	RMBmn	RMBmn	RMBmn	Chg (%)	Chg (%)
GWP & Policy fees (-) Premiums to Reinsurers NWP & Policy fees Chg, in Unearned Premium Res. NEP & policy fees	65,422 (30) 65,452 (72) 65,380	91,956 (32) 91,988 (128) 91,860	95,151 (584) 95,735 (71) 95,664	53,675 (18) 53,693 (165) 53,528	38,281 (14) 38,295 37 38,332	50,843 (238) 51,081 (193) 50,888	44,308 (346) 44,654 122 44,776	56,114 (40) 56,154 (227) 55,927	27 (88) 26 (286) 25	10 (83) 10 18
Investment income	8,362	10,521	12,754	4,114	6,407	6,813	5,941	7,303	23	7
Other income	164	328	192	118	210	101	91	83	(9)	(18)
Total revenue	73,906	102,709	108,610	57,760	44,949	57,802	50,808	63,313	25	10
Claims & Life insurance benefits	(10,763)	(13,250)	(21,178)	(5,908)	(7,342)	(9,896)	(11,282)	(12,046)	7	22
Div. & Int. to PH & Net Inc. in PH Res.	(46,961)	(71,133)	(66,608)	(43,333)	(27,800)	(37,966)	(28,642)	(40,494)	41	7
Ttl. Claims / PH Benefits	( <b>57,724</b> )	( <b>84,383</b> )	( <b>87,786</b> )	( <b>49,241</b> )	( <b>35,142</b> )	( <b>47,862</b> )	(39,924)	( <b>52,540</b> )	32	<b>10</b>
U/W & Policy Acq. Expense	(5,623)	(7,252)	(7,317)	(3,884)	(3,368)	(3,689)	(3,628)	(3,825)	5	4
General & Administrative Expense	(7,206)	(8,410)	(9,229)	(3,925)	(4,485)	(3,998)	(5,231)	(4,517)	(14)	13
Other Expense	(509)	(147)	(199)	194	(341)	108	(307)	(135)	(56)	(225)
Total Expenses	(13,338)	( <b>15,809</b> )	( <b>16,745</b> )	( <b>7,615</b> )	( <b>8,194</b> )	(7,579)	( <b>9,166</b> )	( <b>8,477</b> )	(8)	12
Net profit before Tax Associate P&L and Finance Cost Tax Expense Net profit after Tax Minority interest NP to New China Life Shareholders	2,844 (193) 10 2,661 (1) 2,660	2,517 (262) (5) 2,250 (1) 2,249	4,079 (804) (475) 2,800 (1) 2,799	904 (62) (265) 577 0 577	1,613 (200) 260 1,673 (1) 1,672	2,361 (311) (275) 1,775 0 1,775	1,718 (493) (200) 1,025 (1) 1,024	2,296 (788) 397 1,905 (1) 1,904	34 60 (299) 86 0 86	(3) 153 (244) 7

Source: Company data, ABCI Securities

## New China Life: Embedded Value (EV), Value of New Business (VNB) & New Business Margins (NBM)

(Rmb mn)	1H12	2011	1H11	2010	2009	% НоН	% YoY
ANAV	26,348	21,966	17,673	6,400		20	49
VIF	40,257	36,818	33,798	29,866		9	19
Solvency Cost	(10,456)	(9,793)	(9,149)	(8,181)		7	14
EV	56,150	48,991	42,322	28,085		15	33
EVPS (HK\$)	22.16	19.22	19.70	27.85		15	12
APE	10,040	19,494	11,302	25,297	20,466	23	(11)
VNB	2,338	4,360	4,710	4,741		18	(1)
NBM (APE Basis %)	23.29	22.37	41.67	18.74		0.92	2.30
FYP	22,523	42,863	24,112	55,966	44,769	20	(7)
VNB	2,338	4,360	4,710	4,741		18	(1)
NBM (FYP Basis %)	10.38	10.17	19.53	8.47		0.21	0.54
VNB (HK\$)	0.92	1.71	2.19	4.70		52	(16)

Source: Company data, ABCI Securities

## New China Life: Investment & Yields

(%)	1H12	2011	1H11	2010	2009	% НоН	% YoY
Cash Equivalents	6.8	5.6	5.8	9.3	6.4	1.2	1.0
Deposits	36.0	32.9	30.2	18.9	9.6	3.1	5.8
Bonds	46.8	50.9	52.3	56.2	70.2	(4.1)	(5.5)
Equities	7.4	7.8	9.2	13.3	11.7	(0.4)	(1.8)
Others	3.0	2.8	2.5	2.3	2.1	0.2	0.5
Total Inv'ts (RMB bn)	453	374	335	293	197	21.1	35.4
Net Investment Yield (%)	4.40	4.10	4.00	3.80	3.90	0.30	0.40
Total Investment Yield (%)	3.60	3.80	4.40	4.30	4.60	(0.20)	(0.80)

Source: Company data, ABCI Securities



## New China Life: Operating data


(Rmb mn)	1H12	2011	1H11	2010	2009	% НоН	% YoY
Gross premiums	55,950	94,797	50,662	91,679	65,040	27	10
Individual Agency	23,030	35,871	18,791	28,688	20,248	35	23
Banc.	31,393	56,692	30,731	61,690	43,962	21	2
Wealth Management	622	932	368	221		10	69
Group	905	1,302	772	1,080	830	71	17
FYP Regular	8,653	16,897	9,879	21,889	17,766	23	(12)
% of FYP Ind. Regular	38.4	39.4	41.0	39.1	39.7	(1.0)	(2.6)
# of agents	207,000	200,000	204,380	198,771	226,776	3	1
FYP Regular per agent (Rmb)	41,802	44,390	24,009	47,924	29,637	(6)	74
Individual FYP	5,851	9,758	5,374	10,416	7,299	(40)	9
Individual FYP per agent (Rmb)	28,266	48,790	26,294	52,402	32,186	(42)	7
Persistency 13 mo (%)	90.6	91.5	92.4	91.7	89.4	(0.9)	(1.8)
Solvency (%)	159	156.0	106.1	35.0	36.2	2.8	52.7

Source: Company data, ABCI Securities

New China Life - share price & valuation

		NEW (	CHINA LIFE
		2011	2012E
Share Price	Hi	28.10	36.28
(HK\$)	Lo	23.41	21.55
	Av	24.90	29.04
PEV(X)	Hi	1.47 x	1.50 x
	Lo	1.22 x	0.89 x
	Av	1.30 x	1.20 x
EVPS YoY Growth (%)		-31%	26%
VNB(X)	Hi	5.26 x	6.97 x
	Lo	2.51 x	(1.51x)
	Av	3.38 x	2.80 x
VNB YoY Growth (%)		-64%	2%

Source: Bloomberg, Company data, ABCI Securities





(Rmb mn)	2010	2011	2012E	2013E	1H12
Embedded value					
Adjusted net worth	6,400	21,966	28,081	34,159	26,348
Value of in-force	29,866	36,818	43,330	50,289	40,25
Cost of solvency margin	(8,181)	(9,793)	(10,772)	(12,065)	(10,456
Embedded value	28,085	48,991	60,638	72,383	56,149
Vnb (long term)	4,741	4,360	4,352	4,472	2,419
Multiplier	(2)	(1)	3	3	
New business value (long term)	(9,515)	(5,297)	12,460	12,127	1
Appraisal value	18,570	43,694	73,099	84,510	
EV movement analysis					
Opening embedded value	20,333	28,383	49,290	60,638	48,991
Expected return					
- SHF's	300	333	1,142	1,460	535
- In-force	2,654	3,525	4,234	4,983	1,895
Value of new business (VNB)	5,095	4,681	4,672	4,802	2,419
Inv't r var + Mkt val adj	(203)	(11,894)	3,000	1,500	2,539
Capital raising & dividends	-	25,621	(500)	-	(221)
OpEx var, model chg & others	204	(1,359)	(1,200)	(1,000)	(9)
Closing embedded value	28,383	49,290	60,638	72,383	56,149
EVPS (HK\$)	27.89	19.14	24.18	29.38	22.16
AVPS (HK\$)	18.44	17.07	29.15	34.30	
PEV implied	0.66	0.89	1.21	1.17	
VNB (HK\$)	4.71	1.70	1.74	1.82	
VNB implied (x)	(2.01)	(1.21)	2.86	2.71	
EV contributions 1 (%)					
Expected return on beg EV		14%	11%	11%	5%
IRV + MVA contribution to beg EV		-42%	6%	2%	5%
VNB contribution to beg EV		17%	10%	8%	5%
VNB contribution to beg VIF		16%	13%	11%	6%
EVPS (HK\$) growth		-31%	26%	22%	
EV contributions 2 (%)					
Beginning EV	72%	58%	81%	84%	87%
Expected return					
- SHF's	1%	1%	2%	2%	
- In-force	9%	7%	7%	7%	4%
Inv't r var + mkt val adj	-1%	-24%	5%	2%	5%
Value of new business (VNB)	18%	9%	8%	7%	4%
Capital raising & dividends	0%	52%	-1%	0%	0%
OpEx var, model chg & others	1%	-3%	-2%	-1%	0%
Ending EV	100%	100%	100%	100%	100%

Source: Company data, ABCI Securities estimates





# New China Life Financial Statements

Profit & loss (Rmb mn)						Operating ratios (%)					
	2010	2011	2012E	2013E	2014E		2010	2011	2012E	2013E	2014F
GWP & policy fees	91,956	95,151	104,666	117,226	131,293	Gross written premium growth	40.6%	3.5%	10.0%	12.0%	12.0%
(-) Premiums to reinsurers	32	584	209	234	263	Net earned premium growth	40.5%	4.1%	9.5%	12.0%	12.0%
NWP & policy fees	91,988	95,735	104,875	117,460	131,556						
Chg. in unearned premium res.	(128)	(71)	(105)	(117)	(132)	Claims/benefits - % of NEP	90.9%	91.1%	93.0%	95.5%	96.5%
NEP & policy fees	91,860	95,664	104,771	117,343	131,424	Div to PH & net inc. in PH res. % of NEP	0.8%	0.7%	1.0%	1.0%	1.0%
Investment income	10,521	12,754	16,423	23,174	27,032	Ttl. claim/PH benefits to NEP	91.8%	91.7%	94.0%	96.5%	97.5%
Other income	328	192	173	181	191						
						Claims/benefits - % of total revenue	81.4%	80.2%	80.3%	79.6%	79.9%
Total revenue	102,709	108,610	121,366	140,699	158,647	Net inc. in PH res % of total revenue	0.8%	0.6%	0.9%	0.8%	0.8%
Insurance benefits & claims	(83,611)	(87,151)	(97,437)	(112,063)	(126,824)	Ttl. claim/PH benefits to total					
Investment contract benefits	(772)	(635)	(1,048)	(1,173)	(1,314)	revenue	82.2%	80.8%	81.1%	80.5%	80.8%
Total Claims / PH Benefits	(84,383)	(87,786)	(98,484)	(113,236)	(128,139)						
						Commission cost ratio	7.9%	7.6%	7.0%	7.2%	7.2%
						General & admin. cost ratio	9.2%	9.6%	8.5%	8.5%	8.5%
Commission and brokerage expenses	(7,252)	(7,317)	(7,334)	(8,449)	(9,463)	Other exp. & stat. levy ratio	0.2%	0.2%	0.2%	0.2%	0.2%
Administrative expenses	(8,410)	(9,229)	(8,905)	(9,974)	(11,171)	Operating expense ratio	17.2%	17.5%	15.7%	15.9%	15.9%
Other expenses	(147)	(199)	(210)	(235)	(263)						
Total Operating Expenses	(15,809)	(16,745)	(16,449)	(18,658)	(20,896)	New investment yield	3.8%	4.1%	4.3%	4.2%	4.2%
Finance Expenses	(263)	(806)	(2,417)	(2,701)	(2,860)	Gross investment yield	4.3%	3.8%	3.9%	4.4%	4.3%
Associate / JV - Profits / Losses	1	2	2	2	2						
						Solvency ratio	35.0%	155.9%	181.2%	183.0%	177.6%
Net profit before tax	2,255	3,275	4,018	6,106	6,754						
Tax expense	(5)	(475)	(402)	(1,527)	(1,688)	Balance sheet (Rmb mn)					
Net profit after tax	2,250	2,800	3,616	4,580	5,065		2010	2011	2012E	2013E	2014E
Minority interest	1	1	1	2	2	Cash	27,368	21,095	30,921	51,376	60,839
NP to NCI shareholders	2,249	2,799	3,615	4,578	5,064	Investments	265,498	352,861	444,793	519,471	615,148
						PP&E / Investment Properties	3,435	4,735	4,972	5,220	5,481
Financial summary						Reinsurance Assets	4,535	4,202	4,411	4,646	4,908
	2010	2011	2012E	2013E	2014E	Premium Receivables	979	1,395	1,443	1,588	1,778
EPS (HK\$)	2.23	1.51	1.44	1.86	2.09	Other assets	2,751	2,483	3,889	3,778	7,027
EPS growth (%)	-11.7%	-32.2%	-4.7%	28.9%	12.4%	Total Assets	304,566	386,771	490,430	586,080	695,181
PER (x)	11.1	16.4	21.8	16.9	15.1	Long-term insurance contracts	233,821	292,818	378,258	473,062	577,357
PBV (x)	3.81	2.03	2.11	1.82	1.59	Short-term insurance contracts	804	996	1,094	1,225	1,372
PEV (x)	0.89	1.30	1.30	1.07	0.89	Investment contracts	19,912	19,001	20,049	21,222	22,536
VNB multiple (x)	(0.65)	3.35	4.19	1.14	(1.97)	Borrowings (Sub-debt) Financial assets under repo	0 24,712	5,073 32,481	15,214 33,094	17,000 25,383	18,000 21,740
Dividend per share (HK\$)	0.00	0.00	0.00	0.00	0.00	Unearned premiums	390	504	522	574	643
Yield (%)	0.0%	0.0%	0.0%	0.0%	0.0%	Other Liabilities	18,354	4,585	4,771	5,105	5,459
Payout ratio (%)	0.0%	0.0%	0.0%	0.0%	0.0%	Total liabilities	297,993	355,458	453,001	543,571	647,107
Return on equity (%)	41.6%	14.8%	10.5%	11.5%	11.2%	Net assets	6,573	31,313	37,429	42,509	48,074
Return on assets (%)	0.9%	0.8%	0.8%	0.9%	0.8%	Minority interests	6	7	9	11	13

Source: Company data, ABCI Securities estimates



## **Disclosures**

#### **Analyst Certification**

I, Chan Wing Fu (Francis Chan), being the person primarily responsible for the content of this research report, in whole or in part, hereby certify that all of the views expressed in this report accurately reflect my personal view about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. I and/or my associates have no financial interests in relation to the listed company (ies) covered in this report, and I and/or my associates do not serve as officer(s) of the listed company (ies) covered in this report.

### **Definition of equity rating**

Rating	Definition
Buy	Stock return ≥ Market return rate
Hold	Market return $-6\% \le \text{Stock return} < \text{Market return rate}$
Sell	Stock return < Market return − 6%

Stock return is defined as the expected % change of share price plus gross dividend yield over the next 12 months

Market return: 5-year average market return rate from 2007-2011

Time horizon of share price target: 12-month

#### Definition of share price risk

Rating	Definition
Very high	2.6 ≤180 day volatility/180 day benchmark index volatility
High	$1.5 \le 180$ day volatility/180 day benchmark index volatility $< 2.6$
Medium	$1.0 \le 180$ day volatility/180 day benchmark index volatility < 1.5
Low	180 day volatility/180 day benchmark index volatility < 1.0

We measure share price risk by its volatility relative to volatility of benchmark index. Benchmark index: Hang Seng Index.

Volatility is calculated from the standard deviation of day to day logarithmic historic price change. The 180-day price volatility equals the annualized standard deviation of the relative price change for the 180 most recent trading days closing price.

#### **Disclosures of Interests**

"ABCI Securities Company Limited and/or its member companies ("ABCI") may pursue financial interests to the companies mentioned in the report."

### Disclaimer

This report is for our clients only and is for distribution only under such circumstances as may be permitted by applicable law. It has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. It is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. No representation or warranty, either expresses or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein. This report should not be regarded by recipients as a substitute for the exercise of their own judgment. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas as a result of using different assumptions and criteria. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this report may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, synthesizing and interpreting market information. ABCI Securities Company Limited is under no obligation to update or keep current the information contained herein. ABCI Securities Company Limited relies on information barriers to control the flow of information contained in one or more areas within ABCI Securities Company Limited, into other areas, units, groups or affiliates of ABCI Securities Company Limited. The compensation of the analyst who prepared this report is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues, however, compensation may relate to the revenues of ABCI





Securities Company Limited as a whole, of which investment banking, sales and trading are a part. The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. The price and value of the investments referred to in this research and the income from them may fluctuate. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. For investment advice, trade execution or other enquiries, clients should contact their local sales representative. Neither ABCI Securities Company Limited nor any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this report. Additional information will be made available upon request.

## Copyright 2013 ABCI Securities Company Limited

No part of this material may be (i) copied, photocopied or duplicated in any form by any means or (ii) redistributed without the prior written consent of ABCI Securities Company Limited.

Office address: ABCI Securities Company Limited, 13/F Fairmont House, 8 Cotton Tree Drive, Central, Hong Kong. Tel: (852) 2868 2183